FORM	PTO-1449

IST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S NFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET 239/102 **APPLICANT:**

SERIAL NO.

09/216,062

Guo, Yajun

FILING DATE:

GROUP: JUN 0 9 1999

JUN 0 8 19	(B) pp	(Use several sheets if ne	cessary)	December 18,		1643-166	14	
JUH 11 0 10						TECH	CENTER 1600/2	.900
EXAMBADE EXAMBADE	N. F. F.		·U.S. F	PATENT DOCUMENTS				
EXAMIRADE INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE	
MO	AA	5,669,394	9/23/97	Bergey et al.	128	750	12/22/94>	
nu	AB	5,789,215	8/4/98	Berns et al.	435	172.3	8/7/97	
M	AC	5,591,828	1/7/97	Bosslet et al.	530	387.3	9/29/94~	
MD	AD.	5,635,602	6/3/97	Cantor et al.	i530	391.1	8/13/93	
NO	AE	4,697,600	10/6/87	Cardenas et al.	428	753	6/4/86	
MS	AF	5,241,969	9/7/93	Carson et al.	128	753	6/10/92	
MO	AG 🔭	5,582,996	12/10/96	Curtis	435	7.1	5/27/94	
B . C								1

room	AB	5,789,215	8/4/98	Berns et al.	.435	172.3	8/7/97
N-VO	AC	5,591,828	1/7/97	Bosslet et al.	530	387.3	9/29/94~
MO	AD.	5,635,602	6/3/97	Cantor et al.	1530	391.1	8/13/93
NO	AE	4,697,600	10/6/87	Cardenas et al.	428-	753	6/4/86
Misc	AF	5,241,969	9/7/93	Carson et al.	128	753	6/10/92
MO	AG 🔭	5,582,996	12/10/96	Curtis	435	7.1	5/27/94
M	AH	4,989,614	2/5/91	Dejter, Jr. et al.	128	752	2/23/88-
no	AI	5,060,658	10/29/91	Dejter, Jr. et al.	128	753	7/30/90 '
MSD	AJ '	5,635,600	6/3/97	Fanger et al.	530	387.3	12/27/94
ruc)	AK	5,484,596	1/16/96	Hanna, Jr. et al.	424	277.1	11/1/93
NW	AL	4,844,893	7/4/89	Honsik et al.	424	85.8	10/7/86
140	AM,	5,141,736	8/25/92	Iwasa et al.	530	387.3	12/27/89
Mas	AN -	5,637,481	6/10/97	Ledbetter et al.	435	69.6	9/13/93
NW	AO	5,770,429	6/23/98	Lonberg et al.	435	240.2	10/10/95
100	AP	5,814,318	9/29/98	Lonberg et al	424	184.1	7/22/93
mec	$)_{AQ}$	4,605,011	8/12/86	Naslund	128	752	3/13/84
MO	AR.	5,292,668	3/8/94	Paulus	436	547	12/5/90
W	AS	5,530,101	6/25/96	Queen et al.	530	387.3	12/19/90
MW	AT	5,693,762	12/2/97	Queen et al.	-530	387.3	6/7/95
, mo	AU	5,655,541	8/12/97	Vattuone	128	749	12/29/94
MD.	AV '	5,601,819	2/11/97	Wong et al.	424	136.1	9/14/94 .
						•••••	

DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO	 ∩F PATI	ENTS AND OTHER ITEM	IS FOR APPI	LICANT'S	ATTY. DOCKET 239/102 APPLICANT:		SERIAL NO. 09/216,062		DEIV
101	b Isach	RMATION DISCLOSURE	STATEMEN	∜T	Guo, Yajun FILING DATE:		CPOLID.		
.IUN O	8 1999 8	Use several sheets if ne	cessary)		December 18, 199	8	GROUP: 4643 644	CH CEN	TER 160
ř.	*	7	FOREIG	N PATENT DO	DCUMENTS .		·		
XAMILERAL INITIAL	EMARK	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB CLASS	TRANS YES	LATION NO
MO	AW	WO 95/16775	22.06.95	PCT					
MO	AX	WO 98/24884	11.06.98	PCT			_	<u> </u>	
	AY	EP 0 885-614-A2	16.06.98	EPO			to the second se		
		OTHER DOCUM	AENTS (Inclu	uding Author,	Title, Date, Pertinent	Pages, etc	.)		
^		T							
MU	AZ	Vaughan, Tristan J. et al	l "Human a	ntibodies by des	sign." <i>Nature Biotechn</i>	iology. 16:	535-539 (1998	3	
MU	AZ BA	Vaughan, Tristan J. et al Reiter, Yoram et al., "En fragments." Nature Biot	ngineering ar	tibody Fv fragr	ments for cancer detec	nology, 16:	535-539 (1998 erapy: Disulfic) le-stabili	ized Fv
MI MY MD	BA BB	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Effe	ngineering ar echnology, 1 ective tumor	ntibody Fv fragr 4:1239-1245 (1 vaccines genera	ments for cancer detection 996) ated by in vitro modificated by in vitro modi	tion and the	erapy: Disulfic	le-stabili	
MIT MAD	BA	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Efforbispecific monoclonal at Nestle, Frank O. et al., "	ngineering an echnology, 1 ective tumor ntibodies," No Vaccination	ntibody Fv fragr 4:1239-1245 (1 vaccines general vature Medicine	ments for cancer detections (996) ated by <i>in vitro</i> modificated the second (1997).	tion and the cation of tu 97)	erapy: Disulfic	le-stabili n cytokin	nes and
	BA BB	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Eff bispecific monoclonal and Nestle, Frank O. et al., "Nature Medicine 41 328. Mayordomo, J. I. et al.,	ngineering ar echnology, 1 ective tumor ntibodies," N Vaccination -332 (1998) "Bone marro	ntibody Fv fragr 4:1239-1245 (1 vaccines general dature Medicine of melanoma pow-derived dender	ments for cancer detec 996) ated by <i>in vitro</i> modificated by <i>in vitro</i> modificated by:451-455 (April, 19) atients with peptide- o	cation of tu 97) r tumor lys	erapy: Disulfice imor cells with a sate-pulsed der imour peptide	le-stabili n cytokin ndritic ce	nes and
	BA BB	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Effe bispecific monoclonal at Nestle, Frank O. et al., "Nature Medicine (1) 328. Mayordomo, J. I. et al., protective and therapeut Ostrand-Rosenberg, Suz	ngineering ar echnology, 1 ective tumor ntibodies," Notes accommendation -332 (1998) "Bone marrous anne, "Tumo canne, "Tumo	ntibody Fv fragn 4:1239-1245 (1 vaccines general lature Medicine of melanoma pro- w-derived dender immunity," No or immunothera	ments for cancer detec 996) ated by in vitro modificated. 451-455 (April, 19 atients with peptide- o dritic cells pulsed with ature Medicine, 1:129	cation and the cation of tu 97) r tumor lys synthetic t 7-1302 (19	erapy: Disulfice imor cells with a sate-pulsed der umour peptide 95)	de-stabili n cytokin ndritic ce es elicit	ells,"
	BA BB BC BD	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Eff bispecific monoclonal at Nestle, Frank O. et al., "Nature Medicine (4) 328. Mayordomo, J. I. et al., protective and therapeut	regineering ar echnology, 1 ective tumor ntibodies," Note of the control "Vaccination -332 (1998) "Bone marrous anne, "Tumo, 6:722-727 (A. et al., "Ac duced ICAM	ntibody Fv fragr 4:1239-1245 (1 vaccines general lature Medicine of melanoma pow- derived dender immunity," No or immunothera 1994) tivation of cAM	ments for cancer detections and the second s	cation and the cation of tu 97) r tumor lys synthetic to 7-1302 (19) n antigen-p	erapy: Disulfice amor cells with ate-pulsed der umour peptide 95) presenting cell an Airway Smo	de-stabiling cytoking	ells,"
	BA BB BC BD BE	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Eff bispecific monoclonal at Nestle, Frank O. et al., "Nature Medicine 44 328. Mayordomo, J. I. et al., protective and therapeut Ostrand-Rosenberg, Suz Opinion in Immunology, Panettieri, Jr., Reynold Cells Inhibits TNF-α-In Immunology, 154:2358-	ngineering ar echnology, 1 ective tumor ntibodies," Novaccination -332 (1998) "Bone marroic antitumou anne, "Tumo, 6:722-727 (A. et al., "Ac duced ICAM 2365 (1995)	ntibody Fv fragr 4:1239-1245 (1 vaccines general dature Medicine of melanoma pow-derived dendar immunity," Notes immunothera 1994) tivation of cAM	ments for cancer detections and the company of the	cation and the cation of tu 97) r tumor lys synthetic to 7-1302 (19) n antigen-p ys in Huma	erapy: Disulfice amor cells with ate-pulsed der umour peptide 95) presenting cell an Airway Smo Adhesion," T	de-stabili n cytokin ndritic ce es elicit " Curren ooth Mus he Journ	nes and ells," nt scle eal of
	BA BB BC BD BE BF BG	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Eff bispecific monoclonal at Nestle, Frank O. et al., "Nature Medicine 14 328. Mayordomo, J. I. et al., protective and therapeut Ostrand-Rosenberg, Suz Opinion in Immunology, Panettieri, Jr., Reynold Cells Inhibits TNF-α-In Immunology, 154:2358-Holliger, Philipp et al., "Bubenik, J. et al., "Immunology, 1 et al., "I	regineering ar echnology, 1 ective tumor ntibodies," No Vaccination -332 (1998) "Bone marro ic antitumous anne, "Tumo, 6:722-727 (A. et al., "Ac duced ICAM 2365 (1995) 'Antibodies ounotherapy of	atibody Fv fragr 4:1239-1245 (1 vaccines general dature Medicine of melanoma pow- derived dender immunity," No or immunothera 1994) tivation of cAM 1-1 and VCAM- come back from f cancer using 1	ments for cancer detections ments for cancer detections ments for cancer detections ments and provided in the brink," Nature Bill local administration of	cation and the cation of tu 97) r tumor lys synthetic to 7-1302 (19) n antigen-puys in Huma symphocyte otechnological lymphoid	erapy: Disulfice amor cells with mate-pulsed der umour peptide 95) presenting cell an Airway Smorth Adhesion," Topy, 16:1015-10	de-stabiling cytoking adritic central	nes and ells," nt scle eal of
	BA BB BC BD BE BF BG BH	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Effe bispecific monoclonal and Nestle, Frank O. et al., "Nature Medicine 43 328. Mayordomo, J. I. et al., protective and therapeut Ostrand-Rosenberg, Suz Opinion in Immunology, Panettieri, Jr., Reynold Cells Inhibits TNF-α-In Immunology, 154:2358-Holliger, Philipp et al., "Bubenik, J. et al., "ImmucDNA and constitutively Kubin, Marek et al., "In	regineering ar echnology, 1 ective tumor ntibodies," No Vaccination -332 (1998) "Bone marro ic antitumou canne, "Tumo 6.722-727 (A. et al., "Ac duced ICAM 2365 (1995) "Antibodies of unotherapy of y producing 1 terleukin 12 sections of the echnology of the echn	ntibody Fv fragr 4:1239-1245 (1 vaccines general lature Medicine of melanoma powederived dender immunity," More or immunothera 1994) tivation of cAM- 1-1 and VCAM- come back from f cancer using I (L-2," Immunoli Synergizes with	ments for cancer detections ments for cancer detections ments with period ments with peptide attents with peptide of the catter of Medicine, 1:129 ments at the brink," Nature Biology Letters, 23:287-29 ments for property and the brink, attention of the period of the brink, attention of the bri	tion and the cation of tu 97) r tumor lys synthetic tr 7-1302 (19) n antigen-p ys in Huma ymphocyte otechnolog lymphoid 02 (1990) in Inducin	erapy: Disulfice amor cells with mate-pulsed der umour peptide 95) oresenting cells an Airway Smorth Adhesion," To 2y, 16:1015-10 cells transform	de-stabiling cytoking adritic central	nes and ells," nt scle eal of
	BA BB BC BD BE BF BG BH BI	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Eff bispecific monoclonal at Nestle, Frank O. et al., "Nature Medicine 44 328. Mayordomo, J. I. et al., protective and therapeut Ostrand-Rosenberg, Suz Opinion in Immunology, Panettieri, Jr., Reynold Cells Inhibits TNF-α-In Immunology, 154:2358-Holliger, Philipp et al., "Bubenik, J. et al., "ImmucDNA and constitutively Kubin, Marek et al., "In Cytokine Production of Li, Yiwen et al., "Costin	regineering ar echnology, 1 ective tumor ntibodies," Novaccination -332 (1998) "Bone marro ic antitumou tanne, "Tumo, 6:722-727 (A. et al., "Ac duced ICAM 2365 (1995) 'Antibodies of unotherapy of producing 1 terleukin 12; Human T Cenulation by Contrology, 1	ntibody Fv fragr 4:1239-1245 (1 vaccines general lature Medicine of melanoma power-derived dender immunity," More or immunothera 1994) tivation of cAM- come back from of cancer using I (L-2," Immunola Synergizes with Ills," J. Exp. Me	ments for cancer detections ments for cancer detections maked by in vitro modificated by in vitro modificated by in vitro modificated by in vitro modifications with peptide- or definition cells pulsed with attree Medicine, 1:129 ppy: the tumor cell as a MP-Dependent Pathway-1 Expression and T Ly at the brink," Nature Billional administration of the interestion of the interestion in the brink, and in the b	tion and the cation of tu 97) r tumor lys synthetic tr 7-1302 (19 n antigen-p ys in Huma ymphocyte otechnolog lymphoid 12 (1990) in Inducin	erapy: Disulfice the pulsed der the	de-stability of the cytoking o	nes and ells," nt scle al of -2 n and
	BA BB BC BD BE BF BG BH	Reiter, Yoram et al., "En fragments," Nature Biot Guo, Ya-Jun et al., "Effebispecific monoclonal and Nestle, Frank O. et al., "Nature Medicine 40,328. Mayordomo, J. I. et al., protective and therapeut Ostrand-Rosenberg, Suz Opinion in Immunology, Panettieri, Jr., Reynold Cells Inhibits TNF-α-In Immunology, 154:2358-Holliger, Philipp et al., "Bubenik, J. et al., "ImmucDNA and constitutively Kubin, Marek et al., "In Cytokine Production of	regineering ar echnology, 1 ective tumor ntibodies," Novaccination -332 (1998) "Bone marro ic antitumou ranne, "Tumo, 6:722-727 (A. et al., "Ac duced ICAM 2365 (1995) "Antibodies of unotherapy of y producing 1 terleukin 12 te	atibody Fv fragrad. 1239-1245 (1) vaccines general vaccines de la vaccine de la va	ments for cancer detections and the brink," Nature Biolocal administration of 187/CD28 Interaction of 180/211-222 (1994) Induces Immunity agard.	cation and the cation of tu 97) r tumor lys synthetic to 7-1302 (19 n antigen-pays in Huma symphocyte cotechnolog (1990) in Inducing (1990) in Inducing (1990) of Tumor E	erapy: Disulfice amor cells with mate-pulsed der umour peptide 95) presenting cells in Airway Smorth Adhesion," Toy, 16:1015-10 cells transform g Efficient Programmunogenic pitopes Recognitions of the programmunogenic pitopes Recognitions in the	de-stability of cytoking additic central centr	nes and ells," nt scle eal of -2 n and s," J.

influenced by the level of class I major histocompatibility antigens expressed on the cells," *Proc. Natl. Acad. Sci. USA*, 83:9684-9688 (1986)

Gilliland, Lisa K. et al., "Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells," *Proc. Natl. Acad. Sci. USA*, 85:7719-7723 (1988)

Dranoff, Glenn et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity," *Proc. Natl. Acad. Sci. USA*, 90:3539-3543 (1993)

Chen, Lieping et al., "Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4," *Cell*, 71:1093-1102 (1992)

EXAMINER:

DATE CONSIDERED:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;

Draw line through citation if not in conformance and not considered. Include a copy of this form with next

Information Disclosure Statement - Section 9 PTO-1449

communication to applicant

- 1	FORM DTO 4440			<u> </u>						
	FORM PTO-1449		ATTY. DOCKET	SERIAL NO.						
	A LICT OF BATE	NITC AND OTHER ITEMS FOR ARRIVED AND	239/102	09/216,062						
		NTS AND OTHER ITEMS FOR APPLICANT'S	APPLICANT:							
į.	1 P KINFUR	RMATION DISCLOSURE STATEMENT	Guo, Yajun							
	10, 61		FILING DATE:	GROUP:						
,		(Us several sheets if necessary)	December 18, 1998	1643 (444						
- 1.	JUN N 8 1999 G									
19	. 1 . 🔿 😕 (Baskar, Sivasubramanian et al., "Constitutive expressi	on of B7 restores immunogen	icity of tumor cells expressing						
' ' [BES	truncated major histocompatibility complex class II m	olecules," Proc. Natl. Acad. S.	ci. USA, 90:5687-5690 (1993)						
18	TRADE	Armstrong, Todd D. et al., "Major histocompatibility	complex class II-transfected tu	mor cells present endogenous						
	BQ	antigen and are potent inducers of tumor-specific imm	unity Proc. Natl. Acad. Sci. U	SA, 94:6886-6891 (1997)						
19		Tsioulias, George J. et al., "Expression of HLA Class	I Antigens in Sporadic Adenor	mas and Histologically Normal						
	BR	Mucosa of the Colon," Cancer Research, 53:2374-237	78 (1993)							
20	ALW) DO									
•	BS	Johnstone, Alan et al., "Immunochemistry in Practice,	Chapter 2, pp. 30-47 (Blackw	rell, New York, 2d ed.) (1988)						
21	\longrightarrow BT	Nabel, Gary J. et al., "Direct Gene Transfer for Treatn	nent of Human Cancer," Anna.	ls New York Academy of						
-	BI	Sciences, 772:227-231 (1995)		T 11 2 2 C						
22	BU BU	Allison, James P. et al., "Manipulation of costimulator Opinion in Immunology., 7:682-686 (1995)	ry signais to enhance antitumo	r 1-cell responses," Current						
		Jurianz, Katrin et al., "Adhesive function of Newcastle	digago virus hamagalutinin	in turnor boot interaction "						
23	BV	International Journal of Oncology, 7:539-545 (1995)	e disease virus nemaggiutinin	in tumor-nost interaction,						
1		Hock, Hanno et al., "Vaccinations with Tumor Cells C	Senetically Engineered to Prod	luga Different Cytokinos						
24	$\langle \langle \rangle \rangle$ BW	Effectivity not Superior to a Classical Adjuvant," Can								
25		Mattsson, Ragnar et al., "In Vivo Treatment with Inter								
<i>2</i> 3	. 1	Strong Expression of Major Histocompatibility Comp	lex Class I and II Molecules in	Literus and Decidua But Not						
	W BX	in Extra-Embryonic Tissues," Biology of Reproduction		Cicius and Decidua But 140t						
7.	11.0	Wang, Jianli et al., "Eliciting T Cell Immunity Agains		s by Immunization with						
24	BY	Dendritic Cell-Tumor Fusion Vaccines," The Journal								
00	. ^	Vaughan, Tristan J. et al., "Human Antibodies with Su								
27	H BZ	immunized Phage Display Library," Nature Biotechno		3						
2.2	1.0	Asher, A. L. et al., "Murine Tumor Cells Transduced		osis Factor-α; Evidence for						
28	$ \omega $	Paracrine Immune Effects of Tumor Necrosis Factor a	gainst Tumors," The Journal of	of Immunology, 146:3227-						
ļ	CA	3234 (1991)								
29	N LuO	Yang, Guchen et al., "Antitumor Immunity Elicited by								
<i>'</i>	CB	CD28/CTLA-4 Costimulatory Molecules," The Journal	al of Immunology, 154:2794-2	800 (1995)						
30		Toffaletti, Dena L. et al., "Augmentation of Syngeneio	Tumor-Specific Immunity by	Semiallogeneic Cell						
,	CC CC	Hybrids," The Journal of Immunology, 130:2982-2986								
3	14.00	Ostrand-Rosenberg, Suzanne et al., "Rejection of Mou		fection of MHC Class II						
7	CD	Genes," The Journal of Immunology, 144:4068-4071 (1990)							
30	MA CE	MacLean, James A. et al., "Anti-CD3: Anti-IL-2 Rece	ptor Bispecific Monoclonal A	ntibody," The Journal of						
	· · CE	Immunology, 150:1619-1628 (1993)	TY AA. D7/DD1 I	ALCOTI AAT DIE TIE						
33	10.	Blazar, Bruce R. et al., "In Vivo Blockade of CD28/C Murine Graft-Versus-Host Disease Across the Major I								
	\mathcal{W}	83:3815-3825 (1994)	instocompationity Complex B	arrier in whice, bloom,						
21	1 0	Gansbacher, Bernd et al., "Retroviral Vector-mediated	V-Interferon Gene Transfer in	ito Tumor Cells Generates						
34	M CG	Potent and Long Lasting Antitumor Immunity," Cancel								
1		Bakker, Alexander B. H. et al., "Generation of Antime	elanoma Cytotoxic T Lymphoc	evtes from Healthy Donors						
35	$\lambda \sim \Delta$	after Presentation of Melanoma-associated Antigen-de								
	CH	Research, 55:5330-5334 (1995)								
21	i)	Ockert, Detlef et al., "Newcastle Disease Virus-infecte	ed Intact Autologous Tumor C	ell Vaccine for Adjuvant						
34	CI CI	Active Specific Immunotherapy of Resected Colorecta								
37	(A	Elliott, Bruce E. et al., "Perspectives on the Role of M								
	CI CI	Advances in Cancer Research, 53:181-245 (1989)								
38	10 L	Hellstrom, Karl Erik et al., "Can Co-stimulated Tumo	r Immunity be Therapeutically	Efficacious?," Immunological						
٠ ا	CK	Reviews, 145:123-145 (1995)								
	EXAMINER:	DA'	TE CONSIDERED:	,						
	~ / V	Janame DU	<u> </u>	حف						
	EXAMINER: Init	tial if reference is considered, whether or no	ot citation is in conforma	ance with MPEP 609:						
			Draw line through citation if not in conformance and not considered. Include a copy of this form with next							

r 4				,			
FORM PTO	D-1449		ATTY. DOCKET	SERIAL NO.			
· ,	r	•	239/102	09/216,062			
LIST	OF PATE	ENTS AND OTHER ITEMS FOR APPLICANT'S	APPLICANT:				
	INFO	RMATION DISCLOSURE STATEMENT	Guo, Yajun				
IPA	-		FILING DATE:	GROUP: AND			
<u>/o ; , </u>	<u>~</u>	(Use several sheets if necessary)	December 18, 1998	1642 (644)			
	~ (S)			(()			
JUN 0 8 J	92 L	von Hoegen, Paul et al., "Modification of Tumor Cel	ls by a Low Dose of Newcastl	e Disease Virus," Cellular			
S YW	CE	Immunology, 126:80-90 (1990)					
Ser July	APP.	Linsley, Peter S. & Jeffrey A. Ledbetter, "The Role of	of the CD28 Receptor During	I Cell Responses to Antigen,"			
TRADE	CM_	Annu. Rev. Immunol., 11:191-212 (1993)	3 11 1 1 (T) T) 1 (1)	N / 5 N / 1 174 1001			
M	CN	Hock, Hanno et al., "Interleukin 7 Induces CD4+ T (1298 (1991)	zen-dependent Tumor Rejection	on," J. Exp. Med., 174:1291-			
1.0		Colombo, Mario P. et al., "Granulocyte Colony-stimulating Factor Gene Transfer Suppresses Tumorigenicity of a					
lift.	2co	Murine Adenocarcinoma In Vivo," J. Exp. Med., 173					
1 11							
	CP		Journal of Immunological Methods, 176:145-152 (1994)				
Ω	cQ	Young, James W. et al., "Dendritic Cells as Adjuvant Antitumor Immunity," J. Exp. Med., 183:7-11 (1996)		patibility Complex-restricted			
-108/2	CQ	Zitvogel, Laurence et al., "Therapy of Murine Tumor		Dendritic Cells: Dependence on			
M	CR	T Cells, B7 Costimulation, and T Helper Cell 1-association					
· n /	\	Celluzzi, Christina M. et al., "Peptide-pulsed Dendrit					
ma	CS	Tumor Immunity," J. Exp. Med., 183:283-287 (1996)		,			
A . (/	<u> </u>	Caux, Christophe et al., "B70/B7-2 Is Identical to CD	986 and Is the Major Function	al Ligand for CD28 Expressed			
1000	CT_	on Human Dendritic Cells," J. Exp. Med., 180:1841-					
$V \sim V$		Hurtado, José C. et al., "Potential Role of 4-1BB in T		with the Costimulatory			
	CU	Molecule CD28," The Journal of Immunology, 155:3					
	ļ	Porgadór, Angel et al., "Interleukin 6 Gene Transfect					
Tild.	CV	Malignant Phenotype and Confers Immunotherapeuti	c Competence against Parenta	II Metastatic Cells," Cancer			
$\overline{}$	CV	Research, 52:3679-3686 (1992) Reeves, Mark E. et al., "Retroviral Transduction of H	Juman Dandritia Callaith a	Tumor aggoriated Autions			
and	CW	Gene," Cancer Research, 56:5672-5677 (1996)	iuman Dendrinc Cens With a	i unioi-associated Antigen			
<u>, </u>	 ~ , , , _ 	Luboldt, Hans-Joachim et al., "Selective Loss of Hur	nan Leukocyte Antigen Class	I Allele Expression in			

Advanced Renal Cell Carcinoma," Cancer Research, 56:826-830 (1996)

Antisense Insulin-Like Growth Factor I RNA," Science, 259:94-96 (1993)

Transfected Melanoma Cells," Science, 259:368-370 (1993)

Bode, Christoph et al., "Antibody-directed Fibrinolysis," The Journal of Biological Chemistry, 264:944-948

Hathcock, Karen S. et al., "Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation,"

Quo, Yajun et al., "Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells."

Pownsend, Sarah E. & James P. Allison, "Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-

Leach, Dana R. et al., "Enhancement of Antitumor Immunity by CTLA-4 Blockade," Science, 271:1734-1736

Renner, Christoph et al., "Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human

Allison, James P. & Matthew F. Krummel, "The Yin and Yang of T Cell Costimulation," Science, 270:932-933

Ikeda, Mitsunori et al., "Suppressive Effect of Antioxidants on Intercellular Adhesion Molecule-1 (ICAM-1)

Trojan, Jerzy et al., "Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing

EXAMINER: DATE CONSIDERED:

DATE CONSIDERED:

DATE CONSIDERED:

Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

CY

CZ

DA

DB

DC

DD

DE

DF

DG

58

Sh

w⁰

(1989)

(1995)

Science, 262:905-907 (1993)

Science, 263:518-520 (1994)

T Cells," Science, 264:833-835 (1994)

Chang et al., Gastroenterology, 112(4):A546 (1997)

4	المر د .							
•	FORM PTC)-1449		ATTY. DOCKET 239/102	SERIAL NO. 09/216,062			
	UST (De pate	NTS AND OTHER ITEMS FOR APPLICANT'S	APPLICANT:				
			RMATION DISCLOSURE STATEMENT	Guo, Yajun				
			MATION DISCLOSORE STATEMENT	FILING DATE:	CROLID: ()			
	(N) 3	# 1	(Use several sheets if necessary)		GROUP			
	_ / C ,		Ose several streets if frecessary)	December 18, 1998	1 1843 [67 4]			
		, 1999 gg			,			
иZ	JUN 0	DI_	Hoogenboom, Hennie R. et al., "Antibody phage disp 20 (1998)					
Le3	NO TR	ADEMARK	Golumbek, Paul T. et al., "Treatment of Established F Interleukin-4," Science, 254:713-716 (1991)	Renal Cancer by Tumor Cells I	Engineered to Secrete			
64	NW.	D _{DK}	Freeman, Gordon J. et al., "Cloning of B7-2: A CTLA Proliferation," Science, 262:909-911 (1993)	A-4 Counter-Receptor That Co	stimulates Human T Cell			
65	Z O	DL	Wallich, R. et al., "Abrogation of metastatic propertie		xpression of H-2K antigens			
ule	11.10		following H-2 gene trasfection," <i>Nature</i> , 315:301-315 Shahinian, Arda et al., "Differential T Cell Costimula		eficient Mice," Science,			
٠ _	1000	DM	261:609-612 (1993)					
67	real	$\int_{\rm DN}$	Murphy, Erin E. et al., "B7 and Interleukin 12 Cooper Helper Clones That Are Unresponsive to B7 Costimu					
E.	A . C)DO	Paglia, Paola et al., "Murine Dendritic Cells Loaded I Lymphocytes against Tumor Antigen In Vivo," J. Exp	n Vitro with Soluble Protein P				
69	1	,	Luster, Andrew D. et al., "IP-10, a -C-X-C- Chemoki		pendent Antitumor Response			
W.		DP	In Vivo," J. Exp. Med., 178:1057-1065 (1993)					
20	Ju ()	D 0	Porgador, Angel et al., "Bone Marrow-generated Den		s I-restricted Peptide Are			
.,,•		DQ	Potent Inducers of Cytotoxic T Lymphocytes," J. Exp					
训	N. S.	DR		lation of Interleukin 2 (IL-2) Production Plays a Critical Role in on," <i>The Journal of Experimental Medicine</i> , 179:299-304 (1994)				
	1. C.	1	Gong, Jianlin et al., "Induction of antitumor activity b					
72	M	$\mathcal{I}_{\mathrm{DS}}$	cells," Nature Medicine, 3(5):558-561 (1997)	•	;			
	. 7	7	Melero, Ignacio et al., "Monoclonal antibodies agains	st the 4-1BB T-cell activation i	nolecule eradicate éstablished			
73	M	DT	túmors," Nature Medicine, 3:682-685 (1997)	· .				
74	Noo	DU	Hsu, Frank J. et al., "Vaccination of patients with B-c cells," <i>Nature Medicine</i> , 2(1):52-58 (1996)	ell lymphoma using autologou	s antigen-pulsed dendritic			
25	-		Linsley, Peter S. et al., "CTLA-4 Is a Second Receptor	or for the B Cell Activation An	tigen B7," J. Exp. Med.,			
1)	$\mathcal{W}()$	DV	174:561-569 (1991)		, ,			
74	MD	DW	DeBenedette, Mark A. et al., "Role of 4-1BB Ligand Upregulation on M12 B Lymphomas by cAMP," J. E.					
Ŧ	Nu	DX	June, Carl H. et al., "The B7 and CD28 receptor famil					
~ 1		<i>D</i> 11	Boczkowski, David et al., "Dendritic Cells Pulsed with	th RNA are Potent Antigen-pre	esenting Cells In Vitro and In			
1°	MO	DY	Vivo," J. Exp. Med., 184:465-472 (1996)					
A	MO	DZ	Tykocinski, Mark L. et al., "Antigen-Presenting Cell (1996)	Engineering," American Journ	al of Pathology, 148:1-16			
10	MA	EA	Ulevitch, Richard J. et al., "Hyperexpression of Interf Reorganization of the Cytoskeleton," American Journ					
8	M	EB	Saito, Ichiro et al., "Expression of Cell Adhesion Mol Syndrome," Journal of Clinical Laboratory Analysis,	lecules in the Salivary and Lac				
امم		مديد	Zöller et al., "Interleukin-1 Production by Transforme		Antigen Presentation and T-			
83	NA	EC	Cell-Mediated Anti-Tumor Response," Intl. J. Cancer	r, 50:450-457 (1992)				
B	1/4/		Darlington, Gretchen J. et al., "Expression of Liver Plane National Cancer Institute, 64:809-815 (1980)		•			
- 1 b	\sim		Restifo, Nicholas P. et al., "Molecular Mechanisms U	Ised by Tumors to Escape Imn	nune Recognition:			
34	Ma()		Immunogenetherapy and the Cell Biology of Major H	Iistocompatibility Complex Cl	ass I," Journal of			
	\sim	EE	Immunotherapy, 14:182-190 (1993)	-				

EXAMINER:	DATE CONSIDERED: $21/\omega$
Marane Dir	\sim $8/31/\omega$
EXAMINER: Initial if reference is considered, whether or	not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not	
communication to applicant	• •

4	وَيَوْهُ *		·		
	FORM PTC)-1449 -		ATTY. DOCKET 239/102	SERIAL NO. 09/216,062
	JUST Ĉ		NTS AND OTHER ITEMS FOR APPLICANT'S MATION DISCLOSURE STATEMENT	APPLICANT: Guo, Yajun	
	OIP	E ((Use several sheets if necessary)	FILING DATE: December 18, 1998	GROUP:
	70	-2/			
35	MM 0 8	1999 S	Holliger, Philipp et al., "Retargeting serum immunoglo 15:632-636 (1997)	<u> </u>	
م		F. C.	Merchant, A. Margaret et al., "An efficient route to hu (1998)		
Ç	MADE	EH	McGuinness, Brian T. et al., "Phage diabody repertoire fragments," <i>Nature Biotechnology</i> , 14:1149-1154 (199		ers of bispecific antibody
88	MO	EI	Liu, Margaret, "Transfected human dendritic cells as c		
89	mO	EJ	Tepper, Robert I. et al., "Murine Interleukin-4 Display (1989)	-	
10	2	EK	Fearon, Eric R. et al., "Interleukin-2 Production by Tu- an Antitumor Response," <i>Cell</i> , 60:397-403 (1990)		
11	and	EL	Ertel, Christian et al., "Viral hemagglutinin augments j Immunol., 23:2592-2596 (1993)		
(ટ	no	$\geq_{\rm EM} V$	Willems, Fabienne et al., "Interleukin-10 inhibits B7 a monocytes," Eur. J. Immunol., 24:1007-1009 (1994)		-
13	2	EN	Alderson, Mark R. et al., "Molecular and biological ch Immunol., 24:2219-2227 (1994)		
M	MO	EO	Green, Jonathan M. et al., "Absence of B7-Dependent (1994)	-	•
15	mo	EP	Molecular Biology of the Cell, pp. 47-58 & pp. 276-33 NY & London		
14	Mas	EQ	Huang, Alex Y. C. et al., "Role of Bone Marrow—Der Antigens," Science, 264:961-965 (1994)	rived Cells in Presenting MH	C Class I—Restricted Tumor
		ER			
		ES	•		· · · · · · · · · · · · · · · · · · ·
		ET			
		EU			
		EV			
		EW			
		EX			
		EY			
		EZ			
	-	FA			
		FB			
	1	1			

EXAMINEK:	\sim	× —	DATE CONSIDI	EREL):	6
·	Marane,	Au	DATE CONSIDI	3//00	
EXAMINER:	nitial if reference is consid	lered, whether c	or not citation	is in conformance wit	h MPEP 609;
Draw line thre	ough citation if not in conf	ormance and no	ot considered.	Include a copy of thi	s form with next
communication	on to applicant			· · · · · · · · · · · · · · · · · · ·	